Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD
作者： Cheryl L.P. Vigen , Wendy J. Mack , Richard S.E. Keefe , Mary Sano , David L. Sultzer
DOI: 10.1176/APPI.AJP.2011.08121844
关键词:
摘要: Objective:The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer's disease is unclear. The authors assessed effects time treatment neuropsychological functioning during Clinical Antipsychotic Trials Intervention Effectiveness–Alzheimer's Disease study (CATIE-AD). Method:CATIE-AD included 421 outpatients psychosis or agitated/aggressive behavior who were randomly assigned to receive masked, flexible-dose risperidone, placebo. Based their clinicians' judgment, could discontinue originally medication another medication. Patients followed for 36 weeks, cognitive assessments obtained at baseline 12, 24, weeks. Outcomes compared 357 whom data available least one measure follow-up assessment that took place after they had been...
elsevier.com
sci-hub.se 参考文章(31)
PAOLA ROCCA, FEDERICA MARINO, CRISTIANA MONTEMAGNI, DAVIDE PERRONE, FILIPPO BOGETTO, Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study Psychiatry and Clinical Neurosciences. ,vol. 61, pp. 622- 629 ,(2007) , 10.1111/J.1440-1819.2007.01729.X
A.L. Benton, Development of a multilingual aphasia battery Journal of the Neurological Sciences. ,vol. 9, pp. 39- 48 ,(1969) , 10.1016/0022-510X(69)90057-4
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh, “Mini-mental state” Journal of Psychiatric Research. ,vol. 12, pp. 189- 198 ,(1975) , 10.1016/0022-3956(75)90026-6
Jacqueline S Birks, Cholinesterase inhibitors for Alzheimer's disease Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD005593
A new rating scale for Alzheimer's disease. American Journal of Psychiatry. ,vol. 141, pp. 1356- 1364 ,(1984) , 10.1176/AJP.141.11.1356
John Kennedy, Walter Deberdt, Alan Siegal, Joseph Micca, Elisabeth Degenhardt, Jonna Ahl, Adam Meyers, Christopher Kaiser, Robert W. Baker, Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. International Journal of Geriatric Psychiatry. ,vol. 20, pp. 1020- 1027 ,(2005) , 10.1002/GPS.1397
Hélène Amieva, Sylviane Lafont, Sophie Auriacombe, Constant Rainville, Jean-Marc Orgogozo, Jean-François Dartigues, Colette Fabrigoule, Analysis of Error Types in the Trail Making Test Evidences an Inhibitory Deficit in Dementia of the Alzheimer Type Journal of Clinical and Experimental Neuropsychology. ,vol. 20, pp. 280- 285 ,(1998) , 10.1076/JCEN.20.2.280.1161
Lon S Schneider, M Saleem Ismail, Karen Dagerman, Sonia Davis, Jason Olin, Dennis McManus, Eric Pfeiffer, J Michael Ryan, David L Sultzer, Pierre N Tariot, None, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's Disease Trial Schizophrenia Bulletin. ,vol. 29, pp. 57- 72 ,(2003) , 10.1093/OXFORDJOURNALS.SCHBUL.A006991
Ronald G. Thomas, Julie D. Berg, Mary Sano, Leon Thal, Analysis of longitudinal data in an Alzheimer's disease clinical trial. Statistics in Medicine. ,vol. 19, pp. 1433- 1440 ,(2000) , 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1433::AID-SIM435>3.0.CO;2-F
Neil D. Woodward, Scot E. Purdon, Herbert Y. Meltzer, David H. Zald, A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia The International Journal of Neuropsychopharmacology. ,vol. 8, pp. 457- 472 ,(2005) , 10.1017/S146114570500516X